Register
Login:
Share:
Email Facebook Twitter


Share Views: The Cyber Security opportunity.
What you need to know.


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 98.50Bid: 95.00Ask: 102.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 7.00Spread as %: 7.37%Open: 99.50High: 99.50Low: 97.50Yesterday’s Close: 98.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
98.50

Share Price SpacerBid
95.00

Share Price SpacerAsk
102.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
17,182

Share Price SpacerOpen
99.50

Share Price SpacerHigh
99.50

Share Price SpacerLow
97.50

Share Price SpacerClose
98.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.48m £60.56m 2,000

52 Week High 157.50 52 Week High Date 18-SEP-2015
52 Week Low 82.50 52 Week Low Date 4-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
8 10,500 6,682 -3.397 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

30-Aug-16
14:52:19
97.00
2,500
Sell* 
95.00
102.00
2,425
Trade Type:
Ordinary

30-Aug-16
14:33:05
97.00
2,500
Sell* 
95.00
100.00
2,425
Trade Type:
Ordinary

30-Aug-16
13:21:09
99.65
32
Buy* 
95.00
100.00
31.89
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Tue 11:56Free-MoneyRE: Gr8 price!0.00No Opinion
Nice trade TH2 and looking at the malfunction on the LSE transaction list which is valuing the stock in £'s instead of pence you've made a massive return already :-)
Maybe a sign of things to come. Everything crossed.
Wish I had the funds to top up at this price too. GLA
Tue 11:47TrollHunter2Gr8 price!0.00No Opinion
Nice topup just now, 4131 shares at 99p.
Great value considering the potential on our doorstep here.
Now I continue to wait and see if my research and discussions pays off. GLA
Mon 19:41TrollHunter2RE: AZ Sell to Pfizer99.50No Opinion
Clueless Pomander shows ignorance again.
No one was comparing Summit to AZ.
C.Diff is hugely valuable, $billions!!!
Best of luck all genuine investors.
Mon 16:51pomanderRE: AZ Sell to Pfizer99.50No Opinion
Very different scenario to Summit - approved drugs diversify risk in deal from those in clinical development.

The portfolio comprises the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.

There are deals , but most contain an element of revenue generation from portfolios being acquired, again to diversify risk.

C-Diff is still a binary play - and as such the risk would appear so far, too great for Big-Pharma or even II's to… Read More
24 Aug '16Free-MoneyRE: AZ Sell to Pfizer99.50No Opinion
Thanks for highlighting that Chris.
I did notice that Pfizer seem to be making deals in the past week.
A good sign that confidence is returning to the markets after our Brexit bombshell to the world economies.
Looks a bit like the millennium bug to me.... lots of fear but nothing really changed... business as usual.

Hopefully we'll have our own deal to hit the press pages in the near future. GLA
24 Aug '16ChrisatrdgAZ Sell to Pfizer99.50Strong Buy
AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
per waterloo01 from the other board this morning - makes for a good read:
http://www.investegate.co.uk/astrazeneca-plc--azn-/rns/az-to-sell-antibiotics-business-to-pfizer/201608240700099864H/
Some interesting numbers.

"This includes the upfront payment of $550 million and unconditional payment of $175 million in 2019 (both to be recognised net of the aforementioned product intangible in 2016), the milestones of up to $250 million, the… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.